TrialPath
Long COVID · San Antonio

Long COVID clinical trials in San Antonio

3 recruiting long covid studies within range of San Antonio. Click any trial for full eligibility criteria and contact info.

Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation

NCT05880108 · Post-COVID Conditions, Obesity
Recruiting

The research in this VA Merit will examine the effects of obesity and Post-COVID Conditions (PCC) on physical functioning, health-related quality of life, and adipose tissue inflammatory and cellular senescence profiles in older Veterans. Further, it will evaluate whether a weight loss intervention, including dietary modification and exercise, in obese Veterans with and without PCC will reduce systemic and adipose tissue inflammation and senescence and promote PCC recovery.

PhaseNA
TypeInterventional
Age80 Years
WhereBaltimore, Maryland, United States + 1 more
SponsorVA Office of Research and Development
Tap for details
Apply

NE3107 in Adults With Neurological Symptoms of Long COVID

NCT06847191 · Long COVID
Recruiting

Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call

PhasePhase 2
TypeInterventional
Age18 Years – 69 Years
WherePalo Alto, California, United States + 19 more
SponsorBioVie Inc.
Tap for details
Apply

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287 · Long COVID, Sars-CoV-2 Infection, Coronavirus Infections
Recruiting

The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.

PhasePhase 3
TypeInterventional
Age18 Years
WhereTucson, Arizona, United States + 15 more
SponsorWes Ely
Tap for details
Apply